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Background: Intracoronary transfer and expression of recombinant genes in 
the intact heart is now feasible. In the transplant setting, local modulation 
of host immune responses by a genetically modified allograft may offer an 
attractive alternative to systemic immunosuppression. Methods: We tested 
the efficacy and in vivo effect of intracoronary transfer of two immunosup- 
pressive cytokine genes. First-generation El-deleted adenoviral vectors 
expressing the Epstein-Barr virus interleukin-10 (AdSvIL10) or human 
transforming rowth factor--/31 (AdCMVTGF-/3) were used. Rabbit car- 
diac allografts were transduced during cold preservation by slow (1 ml/min) 
intracoronary infusion of 10 TM pfu/gm diluted viral vectors and then 
implanted heterotopically. Controls included El-deleted adenovirus 
(Ad5d1434) and AdCMVLacZ. Beating allografts were collected on day 4 for 
analysis of gene transfer efficacy and distribution. Additional grafts were 
used for evaluation of alloreactivity/n = 34). Results: Mean allograft viral 
uptake was 81% (up to 91%). Polymerase chain reactions and reverse 
transcription-polymerase chain reactions confirmed the presence and 
expression of both genes in the grafts. /$-Galactosidase staining in 
AdCMVLacZ-infected grafts demonstrated fficient gene expression, which 
was highest (100%) in subepicardial regions. More homogeneous transmyo- 
cardial distribution of the transgene (in 25% to 40% of cells) could be 
achieved by pulsatile slow delivery. Allograft survival was 6.9 - 0.9 days in 
controls (n = 12), 11.1 - 1.7 days in AdCMVTGF-l~-infected grafts (n = 
l l ,  p < 10-4), and 11.2 +- 3 days in AdSvIL10-infected grafts (n = 11,p < 
10-4). Histologic scores (blinded) showed significantly (p < 0.005) higher 
regression coefficients for rejection in controls compared with both cyto- 
kine-transduced groups. Perioperative administration of cyclosporine A
(INN: ciclosporin) to recipients had no effect on survival of AdCMVTGF- 
/]-infected grafts but reduced survival of AdSvIL10-infected grafts. Conclu- 
sions: Intracoronary gene transfer of immunosuppressive cytokines to 
cardiac allografts is efficient and effectively prolongs graft survival. Vectors 
that would induce long-term expression of such genes may make this 
approach clinically applicable. (J Thorac Cardiovasc Surg 1997;114:923-33) 
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W ith the recently developed science of gene therapy, a new era in cardiovascular therapeu, 
tics has been opened. Localized expression of re- 
combinant genes in the transplanted heart may 
contribute to the prevention and treatment of major 
problems in transplantation, such as allograft accel- 
erated coronary atherosclerosis and acute rejection. 
An immediate application of allograft-targeted gene 
therapy is local modulation of the host immune 
response by a genetically altered allograft. Soluble 
proteins ecreted within the transplanted organ may 
act locally and specifically while avoiding systemic 
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Table I. Cytokine levels in protein extract and serum from allografts infected with TGF-[31 and 
vlL-l O- encoding first-generation adenoviral vectors 
Transgene xpression 
Vector Dose n In tissue In serurn 
AdCMVTGFq3 >10 m pfu/gm 5 4 ng/gm (2.2 to 7) Up to 1 ng/ml 
AdCMVTGF-/3 <10 TM pfu/gm 5 1.9 ng/gm (1.6 to 3.6) Not detected 
AdSvIL10 >10 m pfu/gm 4 0.3 ng/grn (0.05 to 0.9) Up to 0.5 ng/ml 
AdSvIL10 <10 ~° pfu/gm 6 Not detected Not detected 
A doubIe-antlbody enzyme-linked immunosorbent assay was used to detect cytokine xpression i allograft protein extract on postoperative day 4. Levels 
shqwn are averaged values for left and right ventricles and intraventricular septum and are expressed as nanograms per gram of donor heart. TGF-/3~ 
expression correlated with the infused quantity of viral vectors and was not detected in significant amount in control AdSd1434-infected grafts, vIL-10 
expression i tissue was undetectable when vector dose was lower than 10 TM pfu/gm of donor heart and minor even at higher doses. However, both cytoldnes 
were detected in the recipient serum. 
side effects and the need for conventional systemi c 
immunosuppresslon. 
Gene transfer into the adult heart has been 
achieved in vivo by direct myocardial injection 1-5 
and more recently by intracoronary infusion. 6-1° The 
latter method is preferable when cons!dering clinical 
application, because direct injection results in un- 
even distribution of transgene xpression and local 
inflammation.4, 5 By way of increasing the efficacy of 
gene transfer and facilitating recombinant DNA 
uptake by target cells, vehicles for gene transfer such 
as cationic liposomes, viral vectors, or a combination 
of both 1° have been successfully used. Given the 
specific attributes of nondividing cardiac cells, re- 
combinant adenoviral vectors emerged as the most 
effective vehicle for transport of genes into the heart 
under both normothermic 7' 9and hypothermic 6 on- 
ditions. To date, studies of gene transfer in the heart 
have been largely limited to the use of reporter 
genes to demonstrate ransgene xpression and the 
efficacy of various transfer strategies. 
To evaluate the applicability of intracoronary 
gene therapy for cardiac transplantation in vivo. we 
constructed first-generation recombinant adenoviral 
vectors encoding two immunosuppressive cytokines. 
viral interleukin-10 (vlL-10) and human transform- 
ing growth factor-/31 (TGF-/31). In addition to well- 
documented immunosuppressive properties in vitro, 
both have recently been shown to inhibit host re- 
sponses in models of alloreactivity in vivo. IL-10. an 
18 kd polypeptide initially described as cytokine 
synthesis nhibitory factor, is best known for its down- 
regulating action on the effector functions of Thl 
helper clones, potently inhibiting production of 
IL-2. TNF-o~, TNF-/3, and interferon-y. The activa- 
tion of monocyte-macrophages is thus effectively 
suppressed, as is the release of monokines and their 
ability to serve as accessory cells for antigen presen- 
tation and stimulation of Th and natural killer 
cells. 11-13 The viral homologue (IL-10 homologue) 
used in this study is encoded by an open-reading 
frame (BCRF1) in the Epstein-Barr virus genome. 14 
This protein shares most of the biologic activities of 
the cellular cytokine. Although it has lower in vitro 
potency, 11 it seems more suitable for targeted im- 
munosuppression in alloreactivity models, because 
of lower mast cell and thymocyte co-stimulatory 
action. TGF-/31 is an omnipresent cytokine, with 
potent down-regulating functions in both cellular 
and humoral al!oreactive pathways. It suppresses 
clonal generation and production of IL-2, IL-6, and 
TNF by alloantigen-specific T lymphocytes at fem- 
tomolar levels 15' 16 and effectively reduces killer 
activity and pore-forming protein gene expression i  
CD8+ lymphokine-activated killer cells. 17 In addi- 
tion, B-cell proliferation and immunoglobulin pro- 
duction are greatly reduced. 
We have previously tested the ability of the new 
El-deleted adenoviral vectors to express the en- 
coded cytqkine genes in cardiac allografts, and have 
developed a model for efficient ex vivo intracoronary 
transfer of the cytokine genes during cold preserva- 
tion. 18 The efficacy of various methods of vector 
delivery, as well as the dose-dependence of trans- 
gene expression, were evaluated. Continuous low 
intracor0nary infusion of diluted vectors was found 
superior to bolus high-pressure injection, resulting 
in absorption of up to 9i% of infused vectors (mean 
80%). This uptake rate was sustained with adminis- 
tered vector doses as high as 6 × 10 l° pfu/gm of 
donor heart. An exposure time of at least 20 minutes 
was required to obtain detectable transgene xpres- 
sion in the allografts and recipient serum on post- 
operative day 4. This method of delivery resulted in 
measured tissue protein levels, as shown in Table I. 
In the present study we used the slow intracoro- 
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nary vector delivery method and examined the re- 
sulting transmyocardial distribution and magnitude 
of expression of a reporter gene, the Escherichia coIi 
(E. coli) 13-galactosidase. Transcription of the cyto- 
kine genes was documented by reverse transcrip- 
t ion-polymerase chain reaction (RT-PCR).  We 
then sought to determine whether immunosuppres- 
sive cytokine genes similarly administered can pro- 
long allograft survival in vivo. 
Methods 
Viral vectors. A recombinant adenovirus expressing 
vIL-10 (AdSvIL10) was constructed as follows: A 520 bp 
EcoRI fragment containing the Epstein-Barr virus 
BCRF1 open reading frame (vIL-10) derived from 
pcDSRa-BCRF114 (kindly provided by Dr. Kevin Moore, 
DNAX, Palo Alto, Calif.) was first cloned into a modified 
pBS SK+ (Stratagene Inc., La Jolla, Calif.), with its KpnI 
site changed to a BglII site, resulting in pBS-BCRF1. Then 
the BglII to Ba~HI BCRF1 containing fragment from 
pBS-BCRF1 was inserted between the SV40 early pro- 
moter and the SV40 polyA site of pAdDB, pAdDB is 
derived from a pUC-based plasmid pad2.1719 containing 
Ad2 left end sequences from nucleotide 1 to 6228 
(HindIII site) with its E1 region from nueleotide 341 to 
3321 replaced by an expression cassette containing an 
SV40 early promoter, splice site, and polyA site from 
pXPRS+ (Clonteeh Inc., Palo Alto, Calif.). In the result- 
ant plasmid pAdSvlL10, the direction of vIL-10 gene 
transcription is leftward relative to the standard Ad2 map. 
AdSvIL10 recombinant virus was constructed by eo-trans- 
feetion of 293 cells (that constitutively express E1 pro- 
teins) with pAdSVvIL10 and d1309 viral DNA a° cut with 
XbaI and ClaI. Clones of recombinant virus were identi- 
fied by restriction digestion and Southern blot analysis of 
Hirt DNA from infected 293 cells. 
The AdCMVTGF-/31 was constructed as follows: the 
1.3 kb hTGF-/31 complementary DNA (cDNA) fragment, 
flanked by EcoRI sites, was cloned into the EcoRI site of 
pHCMVspllacZ, al replacing the LacZ gene. The result- 
ant plasmid pHCMVhTGF-/3 has the human TGF-/3 gene 
downstream from the CMV IE promoter and contains the 
SV40 splice signal and polyA site. Co-transfection i to 
293 cells with pHCMVhTGF-/3 and truncated 1309 viral 
DNA resulted in generation of AdCMVTGF-/3 v 
The control "empty" virus Ad5d1434 has deletions of 
the entire E IA  and most of the E1B region. 2a The 
AdCMVLacZ virus, which encodes the E. coli LacZ gene 
with an N-terminal nuclear localization signal, was con- 
structed by co-transfection f pACCMV/3gal (kindly pro- 
vided by Robert D. Gerard) and pJM17. 23 
All recombinant viruses were plaque purified on 293 
cells three successive times and grown into a high titer 
stock of greater than 10 ~° pfu/ml as assayed by plaque 
formation on 293 cells. The ability of cytokine-encoding 
vectors to express the transgenes was confirmed by en- 
zyme-linked immunosorbent assay detection of both 
vIL-10 and TGF-/31 24 hours after infection in 293 cell 
culture supernatant. 
Experimental procedures. The rabbit heterotopic 
model of cardiac transplantation was previously de- 
scribed, is In brief, New Zealand White donors (1.7 to 2 
kg, Charles River Laboratories, St. Constant, Quebec, 
Canada) and recipients (5 to 5.5 kg, Irish Farms, Norco, 
Calif.) were purchased from genetically and geographi- 
cally unrelated vendors. All animals received humane care 
in compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institutes of Health (NIH Publication No. 86-23; revised 
1985). General anesthesia was induced intravenously with 
ketamine (10 mg/kg) and acepromazine (1 mg/kg) and 
maintained with inhaled 1.5% isoflurane in oxygen by 
means of mechanical ventilation. Heparin (200 mg/kg) 
was given intravenously to both donors and recipients. 
Recipients received cefazolin (40 mg/kg) before incision. 
After sternotomy, the donor heart was arrested with 
University of Wisconsin solution (15 ml), then excised and 
preserved in University of Wisconsin solution at 4 ° C. 
After intracoronary gene transfer (see below), donor 
hearts were transplanted in recipients in the heterotopic 
cervical position, by anastomosing the donor aorta and 
pulmonary artery to the recipient right carotid artery and 
jugular vein, respectively. Topical cooling of donor hearts 
was maintained throughout the procedure. Ischemic time 
was 50 to 60 minutes. All allografts resumed spontaneous 
vigorous contraction within minutes of reperfusion. Ces- 
sation of mechanical ctivity before day 4 occurred in 10% 
and was considered to be due to technical failure. 
Intracoronary gene transfer. During preservation at4 ° C, 
the donor aorta was cannulated. Viral vectors were resus- 
pended in 20 ml cold University of Wisconsin cardioplegic 
solution and administered by slow intracoronary infusion 
at 1 ml/min. The total vector dose of 10 l° pfu/gm of donor 
heart (mean weight 5 to 5.5 gin) was infused over 20 
minutes. This constitutes an estimated multiplicity of 
infection of 20 viral particles per cell. After administration 
of at least 10 ml, coronary sinus effluent was collected for 
determination of viral titers. 
Specimen processing. Allografts were inspected twice 
daily by direct palpation and given a score for mechanical 
activity, size, and consistency. For evaluation of cytokine 
transcripts and reporter gene expression, specimens were 
collected on postoperative day 4. For evaluation of allo- 
genicity, other grafts were collected when mechanical 
activity became imperceptible. Transmural specimens 
from the left and right ventricular f ee walls and intraven- 
tricular septum were collected for each allograft. 
PCR. Flanking primers were designed for internal re- 
gions of both transgenes: for vIL-10--a 461 bp region 
(sense: 5'-ATGGAGCGAAGGTTAGTGGTC A-3', 
antisense: 5'-CCTGGCTTTAATTGTCATGTATGCT- 
3'); for TGF-/31--a 243 bp region (sense: 5'-GCCCTG- 
GACACCAACTATTGC-3', antisense: 5'-TTGCGGC- 
CCACGTAGTACA-3'). DNA was extracted from 
specimens nap-frozen after cessation of mechanical ac- 
tivity, by the proteinase K incubation method: samples 
were crushed to fine powder and suspended in digestion 
buffer (100 mmol/L NaC1, 10 mmol/L tromethamine-C1, 
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25 mmol/L ethylenediaminetetraacetic acid, 0.5% sodium 
dodecylsulfate, pH 8.0, 0.1 mg/ml proteinase K) at 80 
mg/ml for 1 hour. Phenol/chloroform/isoamyl alcohol 
(25:24:1) was added in equal volume, and then the upper 
aqueous phase was separated by centrifugation. This step 
was repeated with and without chloroform; then two 
volumes of 100% ethanol and 10% sodium acetate (pH 
5.2) Were added at -20 ° C for 1 hour. DNA precipitate was 
dried and resuspended in water at room temperature. 
PCR was performed in a DNA thermal cycler (Perkin- 
Elmer, Norwalk, Conn.) and consisted of 30 cycles (dena- 
turing: 94 ° C-I'; annealing of primers: 55 ° C-I'; and ex- 
tension: 72°C-1'). PCR products were separated by 
electrophoresis in 1.2% agarose gel and then stained with 
ethidium bromide. Expression plasmids used for vector 
construction served as positive controls. 
RT-PCR. Total RNA was isolated from frozen speci- 
mens collected 4days after the operation, by means of the 
lithium chloride/urea method. 24 cDNA was obtained by 
random primer reverse transcription of RNA using 200 
units of SuperScript II Reverse Transcriptase (Gibco- 
BRL RT-PCR kit, Gaithersburg, Md.). The RNA/primer 
mixture was incubated at 42 ° C for 60 minutes, then 70 ° C 
for 15 minutes, cDNA was amplified with 1 unit of Taq 
DNA polymerase (Gibco-BRL) and 0.2 p.M of each 
primer to a final volume of 100/xl, using the two specific 
primers described above for vIL-10 and human TGF-131. 
Thirty-five cycles of amplification were carried out in a 
thermocycler (GeneAmp PCR System 9600, Perkin- 
Elmer) and consisted of denaturing at 94°C for 30 
minutes, primer annealing at 55°C for 45 minutes, and 
primer extension at 72 ° C for 30 minutes. Before cycling, 
the reaction mixtures were preheated at 94°C for 2 
minutes and after amplification an extra 10 minutes were 
added for extension at 72 ° C. RT-PCR products were run 
on 1.2% agarose gel, transferred tonylon membranes, and 
probed for the presence of vIL-10 and TGF-/31 using a 
random primer (32p) dATP-labeled probe. 
[3-Galactosidase expression. Normally contracting grafts 
were collected on postoperative day 4, and specimens 
were embedded in ornithine carbamoyltransferase 
(O.C.T.), then rapidly frozen in liquid nitrogen. Sections 
10 ~m thick were fixed in 0.2% glutaraldehyde and 2% 
formaldehyde in phosphate-buffered saline (PBS) solution 
for 5 minutes at 4 ° C. After being washed three times with 
phosphate-buffered saline solution at room temperature, 
the sections were stained for 13-galactosidase by overnight 
incubation with X-gal (5-bromo-4-chloro-indolyl /3-D-ga- 
lactopyranoside) at 37 ° C. Cells expressing ¢3-galactosi- 
dase showed intense blue staining. To quantify expression, 
positive as well as total cells were counted per high-power 
field (× 400). At least 10 fields per specimen from different 
subepicardial nd subendocardial areas were examined. 
Histologic examination. After graft failure, transmural 
specimens from the left and right ventricular free walls 
and intraventricular septum were fixed in 10% formalin. 
Slices 10 txm thick were stained with hematoxylin and 
eosin. Rejection scores were assigned by a pathologist 
unaware of study design, based on the standard grading 
nomenclature established by the International Society for 
Heart TransplantationY 
Data analysis. Data are expressed as mean + standard 
deviation. Allograft survival curves produced with the 
Kaplan-Meier product limit method were compared with 
the Mantel-Cox log rank test. Rejection slope coefficients 
were compared with the use of one-way analysis of 
variance and significant differences were further tested by 
means of the Bonferroni t test for multiple comparisons. 
Significance level was set at p < 0.05. 
Results 
Vector absorption, detection, and expression. 
Using intracoronary delivery at a rate of 1 ml/min 
and vector quantity of 101° pfu/gm of donor heart, 
average uptake of vectors by the grafts (defined as 
coronary sinus output titer × 100/delivered titer) 
was 81% _+ 5.6%. All four vectors were absorbed 
equally. Inserted cytokine DNA sequences were 
detected by amplification (PCR) in all grafts in- 
fected with the AdSvIL10 and AdCMVTGF-/3 (Fig. 
1, a), but not in controls. This finding is consistent 
with the presence of both transferred genes in graft 
tissue after cessation of mechanical activity. RT- 
PCR (Fig. 1, b) demonstrated the presence of both 
cytokine transcripts in the grafts, confirming suc- 
cessful gene transfer and expression in myocardial 
cells on postoperative day 4. 
Distribution and magnitude of transgene xpres- 
sion. The slow intracoronary flow of vectors 
brought about uneven distribution of expression of 
the/3-galactosidase reporter gene (Fig. 2, A). Sub- 
epicardial perivascular regions expressed/3-galacto- 
sidase in up to 100% of cells (Fig. 2, B); however, 
the amount of stained cells in mid-wall and suben- 
docardial regions was only 5% to 20% (mean 12%, 
Fig. 2, C). In view of this, we attempted to achieve 
more homogeneous transgene xpression through- 
out the myocardium by increasing perfusion pres- 
sure without reducing total exposure time. This was 
accomplished by intermittent external compression 
of the left ventricle during the slow inflow of vectors, 
thus simulating higher pulsatile pressure. Allografts 
infected in this manner showed more even distribu- 
tion of/3-galactosidase expression, as shown in Fig. 
2, D. Average ratio of cells expressing/3-galactosi- 
dase was 40% in subepicardial regions and 25% in 
the inner subendocardial regions. 
Allograft rejection. Grafts for evaluation of allo- 
reactivity were infected by means of the slow infu- 
sion method (1 ml/min). Allografts infected with the 
"empty" Ad5d1434 virus (n = 12) maintained me- 
chanical activity for 6.9 + 0.9 days. Progressive 
enlargement, hardening, and shallowness occurred 
in all control grafts starting on postoperative day 5. 
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Fig. 1. a, Detection of expected cytokine gene sequences by PCR at 461 bp (vIL-10) and at 243 bp 
(TGF-/31) in DNA extract from representative corresponding cardiac allografts collected after c ssation of 
mechanical activity. DNA was visualized by ethidium bromide staining. Lane 1, Ad5d1434 (control virus) 
tested negative. Lane 2, AdSvIL10-infected graft. Lane 3, Ladder marker. Lane 4, AdCMVTGF-/3-infected 
graft. The corresponding plasmids served as positive controls: Lane 5, The TGF-/31-encoding plasmid 
(pHCMVAdhTGF). Lane 6, The vlL-10 encoding plasmid (pAdSvIL10). b, Detection of gene expression 
in allografts collected 4 days afteradenoviral infection. Total RNA was extracted from frozen specimens, 
reverse-transcribed, amplified by PCR, and probed for the presence of vIL-10 and human TGF-/31. Lane 
1, Ladder marker. Lanes 2 and 3, Ad5d1434-infected graft (negative control). Lanes 4 and 5, AdCMVLacZ- 
infected graft. Lanes 6 and 7, AdCMVTGF-/3-infected graft demonstrates transcription ofTGF-/31 (lane 
6) but not vIL-10 (lane 7). Lanes 8 and 9, AdSvIL10-infected graft demonstrates transcription of vIL-10 
(lane 8) but not TGF-~31 (lane 9). 
Maximal allograft survival in this group was 9 days 
(n = 1), with 10 of the 12 grafts beating for 6 to 7 
days. 
Mean survival for AdCMVTGF-/3-infected grafts 
(n = 11) was 11.1 _+ 1.7 days (range 9 to 15.5 days, 
p < 10 .4 compared with controls). All but one graft 
in this group survived 10 days or longer, with clinical 
rejection starting at 8 to 13 days. 
AdSvlL10-infected allografts (n = 11) survived 
for an average of 11.2 _+ 3 days (p < 10 .4 compared 
with controls). Although graft survival was distinctly 
prolonged by vIL-10 gene transfer, allografts in this 
group seemed to fall in two separate categories, 
surviving either 8 to 9.5 days (n = 7) or 14 to 16.5 
days (n = 4). This finding could not be attributed to 
any specific divergence in treatment, including vec- 
tor delivery, ischemic time, or other surgical or 
experimental factors. Clinical allograft deterioration 
started, correspondingly, either on day 7 or after day 
13 postoperatively. Kaplan-Meier cumulative sur- 
vival curves were derived for the three groups (Fig. 
3). 
Histologic rejection was assessed blindly by a 
pathologist unaware of study design. Lowest, high- 
est, and majority scores were assigned. Left and 
right ventricular and septal specimens were ana- 
lyzed, and averaged "majority" scores for each graft 
were used. Scores averaged grade 3 to 3B and were 
similar among the three study groups. Rejection 
scores were plotted against allograft survival period 
for the individual grafts, then average slopes were 
compared among the study groups (Fig. 4). Average 
rejection slopes for both AdCMVTGF-/3 and 
AdSvIL10-infected grafts (0.3 + 0.06 and 0.23 + 
0.05, respectively) were significantly lower than for 
controls (0.46 _+ 0.15, p < 0.001 and p < 0.0005, 
respectively). 
A predominant part of the immune modulation 
by both TGF-/31 and IL-10 is effected by alteration 
of antigen-presenting cellfunction. Because antigen 
recognition and immune activation commence im- 
mediately after exposure to alloantigen, we specu- 
lated that these occurrences within the 6 to 10 hours 
before the rise of transgene protein expression may 
limit the in vivo efficacy of isolated gene therapy. To 
perturb immunity at this stage, cyclosporine A 
(INN: ciclosporin) was administered in the periop- 
erative period to recipients of AdCMVTGF-/3 and 
AdSvIL10-infected grafts: intravenous doses of 5 
mg/kg were administered 1 hour before the opera- 
tion and repeated after the completion of the oper- 
ation. Serum levels of cyclosporine A before the 
second dose were 150 to 170/xg/L, a range that has 
been shown to prevent rejection of cardiac allografts 
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Fig. 2. Patterns of reporter gene expression i  cardiac allografts infected with AdCMVLacZ using various 
intracoronary slow-administration techniques. Grafts were collected 4 days after intracoronary transduc- 
tion with AdCMVLacZ. A, Continuous low-pressure intracoronary delivery at 1 ml/min results in uneven 
myocardial distribution: B, Extremely efficient ransfer in subepicardial perivascular areas but (C) much 
lower expression in inner portions of the left ventricle. D, Intermittent external compression was used to 
increase delivery pressure without reducing the duration of exposure. This resulted in more homogenous 
transmural distribution. Solid arrows, Epicardium. Broken arrows, Endocardium. 
in New Zealand White rabbits. 26 As shown in Fig. 5, 
survival of AdCMVTGF-/3-infected grafts (n = 4) 
was not affected by perioperative administration of
cyclosporine A. However, an unexpected reduction 
in survival of AdSvIL10-infected allografts (n = 4, 
p = 0.003) was observed, to the level of control 
Ad5d1434-infected grafts. 
Discussion 
The present study constitutes a first report of a 
working allograft-targeted gene therapy strategy in 
the heart transplant setting. It demonstrates the 
ability of exogenous immunosuppressive cytokine 
genes delivered by ex vivo intracoronary gene trans- 
fer to effect a significant inhibitory action on acute 
allograft rejection. Adenovirus-mediated delivery of 
both the vIL-10 and human TGF-/3~ genes during 
allograft cold preservation resulted in efficient vec- 
tor uptake, internalization, transcription, and intra- 
graft expression of both cytokines. Prolongation of 
allograft survival, although temporary, was evident 
and highly significant, suggesting that this approach 
may be used to facilitate transplantation. 
Recent studies from this and other laboratories 
have qualitatively demonstrated the feasibility of 
intracoronary myocardial gene transfer, using cat- 
ionic liposomes and adenoviral vectors. 6'8-10, 27 Rep- 
lication-defective adenoviral vectors are currently 
the most efficient vehicle for in vivo gene transfer 
into nondividing cells such as myocytes, being at 
least 20 times more potent han the newest liposo- 
real compounds. 2sExogenous DNA up to 8.3 kb can 
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Fig. 3. Kaplan-Meier survival curves for control (Ad5d1434), AdSvIL10, and AdCMVTGF-/31-infected 
allografts. Significant prolongation of survival was observed with both cytokines but was more consistent 
with TGF-/31. 
be Used to replace the viral early expression regions 
E1 and E3 or partly E4. 29 Although the use of viral 
vectors in vivo raises safety concerns, the wide- 
spread type 5 adenovirus has not been associated 
with any known malignancies and has been used for 
routine vaccination in human beings with no appar: 
ent side-effects. 3° The viral particle enters the cell by 
way of a two-stage process: high-affinity membrane 
binding occurs by way of the fiber protein, a step 
that is unaffected by hypothermic conditions. Inter- 
nalization is then mediated by interaction of the 
penton base with cellular alpha v beta 3 and 5 
integrins (the vibronectin-binding proteins), 31 This 
process is energy-dependent a d occurs under nor- 
mothermic onditions after graft reperfusion. After 
endocytosis and cytoplasmic release of the fiber, 
pento n base, and capsid-stabilizing proteins, up to 
80% of internalized viral particles reach the nuCleus, 
where the viral genome remains episomal, thus 
resulting in transient expressionY This short-lived 
duration of transgene xpression currently limits the 
potential usefulness of first-generation adenoviral 
vectors for in vivo gene therapy. 
The current study first evaluated the magnitude 
and transmural distribution of gene expression in 
allografts! infected during cold preservation with 
adenoviral vectors encoding a reporter gene (/3- 
gaiactosidase). The use' of reporter genes allows 
direct visualization of the transduced cells by enzy- 
matic staining, thus having the advantage of easy 
localization of gene expression. The efficacy of gene 
transfer obtained in the present study by slow low- 
pressure intracoronary infusion of vectors under 
hypothermic onditions is comparable with that 
previously reported with normothermic transcathe- 
ter intracoronary infusion in vivo 7 and represents 
the highest myocardial transduction ratios to date. 
However, transmural expression of vectors adminis- 
tered in this fashion was not homogeneous: whereas 
subepicardial perivascular regions were transduced 
with very high efficacy,/3-galactosidase expression i  
subendocardial reas was considerably lower. This 
finding may be due to high-affinity adherence of the 
vectors to proximal first-encountered cells, made 
possible by the slow delivery rate. When soluble 
cytokine genes are being transferred, this may not 
necessarily essen an in vivo effect, because secreted 
proteins may act within the graft without requiring 
uniform myocardial expression. Nevertheless, ome 
gene transfer applications (e.g., neoangiogenesis or 
enhancement of contractile function) may require 
homogeneous transgene distribution. We demon- 
strated that a more uniform distribution of trans- 
gene expression throughout the myocardium can be 
achieved by pulsatile administration ofthe vectors at 
higher perfusion pressure without reducing the du- 
ration of inflow, a method easily applicable clini- 
cally. 
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Fig. 4. Histologic rejection scores for allografts infected with Ad5d1434, AdCMVTGF-/31 and AdSvIL10, 
using the International Society for Heart Transplantation classification. Rejection scores and allograft 
survival are expressed as mean -+ standard eviation. Scores were similar between the study groups, but 
rejection slopes were significantly lowered by immunosuppressive cytokine gene transfer. 
In the present study, an initial 60% prolongation 
of allograft survival was followed by graft rejection, 
suggesting that cytokine levels were temporarily 
sufficient to achieve an in vivo effect. The time 
course of graft failure corresponds to the time frame 
of adenoviral vector transgene xpression as docu- 
mented by reports of in vivo gene transfer. 6'7, 33 It is 
therefore plausible that the decline in cytokine 
expression be a reason for graft failure. The mech- 
anism causing the transience of expression of genes 
transferred by adenoviral vectors is not fully under- 
stood. Cellular and humoral host immune responses 
have been shown to be activated against both the 
adenovirus group antigen and the encoded trans- 
gene within 2 weeks of intramuscular vector admin- 
istration in mice, and systemic immunosuppression 
has significantly prolonged gene expression. 34How- 
ever. liposomal gene delivery results in only mar- 
ginal prolongation of expression. More recently, it 
has been suggested that humoral immune response 
to non-self tranSgene-encoded proteins, rather than 
viral proteins, is responsible for this observed insta- 
bility of transgene xpression, as well as the relative 
inefficacy of repeated vector administration. 35 
Whereas TGF-/31 has down-regulating effects on 
B-cell proliferation and antibody production, vIL-10 
actually promotes differentiation and proliferation 
of B cells along their maturation stages. 12 This 
opposed action on humoral responses might explain 
the more consistent prolongation of allografl sur- 
vival observed with TGF-/31. The finding that trans- 
fer of a self-protein gene results in stable long-term 
expression under identical conditions in immuno- 
competent animals 35 is encouraging, because most 
candidates for clinical gene therapy applications are 
ubiquitous proteins such as cytokines, enzymes, re- 
ceptors, and growth factors. 36 Future research 
should evaluate the usefulness of gene therapy 
strategies inducing overexpression f such self-pro- 
teins. 
A vector absorption ratio above 80% was main- 
tained in the present study with all four vectors. We 
previously found the absorbed fraction of adenoviral 
vectors administered by ex vivo slow intracoronary 
infusion to be remarkably constant over a wide 
range of doses, despite hypothermic (4 ° C) condi- 
tions. Moreover, expression of TGF-/31 corre- 
lated with the infused (and absorbed) quantity of 
AdCMVTGF-/3 in a dose-dependent manner. TM
These results are encouraging, because high doses 
of vectors may be administered without sa urating 
all0graft receptors and may increase the initial 
amount of expressed prote in. The detection of both 
expressed cytokines in corresponding recipient se- 
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Fig. 5. Average duration of a!lograft survival: Perioperative administration of cyclosporine A (CSA) did 
not notably alter survival Of AdCMVTGF-infected allografts, but survival of AdSvIL10-infected grafts was 
reduced compared with that observed in control grafts. 
rum (see Table I) suggests that a significant amount 
of protein is secreted by the allografts. Although it 
cannot be ruled out that part of this protein is 
secreted by remote recipient cells infected with virus 
shed from the coronary bed during graft reperfu- 
sion. we believe this amount o be small, based on 
the small volume of the rabbit coronary tree and the 
high dilution of administered virus. However. we 
cannot rule out the possibility of a systemic immu- 
nosuppressive effect mediated by the secreted cyto- 
kine fraction. In a recent report, prolongation of the 
survival of nonperfused neonatal mouse donor 
hearts transduced by retrovirus-mediated transfer 
of the vIL-10 gene was found to be due to local 
rather than systemic immunosuppression. 37 How- 
ever. vIL-10 was not detectable in the serum of 
recipient mice in that report. 
Perioperative administration of high-dose cyclo- 
sporine A failed to further prolong allograft sur- 
vival. The rationale for cyclosporine A administra- 
tion at this time was to provide transient inhibition 
of cellular immune activation and antigen-present- 
ing cell function for the duration of initial transcrip- 
tion and translation of the inserted genes. These 
processes occur immediately after graft reperfusion 
and, therefore, are not within the time frame of 
transgene xpression. Although cyclosporine A had 
no effect on survival of AdCMVTGF-/3-infected 
grafts, the survival of AdSvIL10-infected grafts was 
significantly shortened by perioperative administra- 
tion of cyclosporine A. Inadequate time frame or 
magnitude of cycl0sporine A-induced immunosup- 
pression may partly explain these results; however, 
an important difference between the two cytokines 
lies in their different interspecies homology. 
Whereas TGF-/31 is highly similar between species, 
IL-10 varies tructurally and functionally} 3 In our 
rabbit model, vIL-10 allogenicity may have precipi- 
tated an accelerated immune response to this non- 
self encoded protein in the setting of delayed anti- 
gen presentation effected by cyclosporine A. A 
recent finding by van Bergen and associates38 may 
provide a clue to the mechanism of ILq0-mediated 
acceleration of graft rejection i the presence of 
antigen-presenting cellsuppression. Although IL-10 
is known to inhibit antigen-induced T-cell prolifer- 
ation in the presence of antigen-presenting cells, the 
authors found that in the absence of antigen-pre- 
senting cells, this cytokine strongly stimulated pro- 
liferation of CD8+ cytotoxic T-lymphocyte clones. 
These in vitro results suggest a dichotomy of IL-10 
immunomodulatory function early and late in the 
allogeneic immune response. To determine the 
mechanisms by which the two cytokines exert their 
9 3 2 Brauner et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
December 1997 
immunosuppressive effect in vivo, further research 
will include an analysis of the graft cellular infiltrate 
and quantitatio n of alloantigen,specific ytotoxic 
and helper T-cell precursors, in addition to cytokine 
expression profiles within the grafts. 
The ability to transfer working recombinant genes 
to cardiac allografts at the time of preservation, as 
demonstrated in the present study, has potentially 
far-reaching clinical and research applications. In 
the long term, this approach may be part of a 
strategy to provide a milieu in which organ-specific 
tolerance may be achieved by the use of adjuvant 
time-limited measures. In addition, therapies involv- 
ing gene transfer can be envisioned that would 
improve early posttransplantation myocardial con- 
tractility and endothelial function or prevent late 
allograft vasculopathy. However, the limitations of 
currently available vectors must first be overcome to 
improve the stability of transgene xpression. Prom- 
ising strategies aimed at extending the expression of 
transferred gene s include further deletions in 
second- and third:generation adenoviruses, 39' 40 sys- 
temic immunosuppression, 34 use of Self-protein en- 
coding genes, 35 use of genome-integrating vec- 
tors, 37'41 and construction of new recombinant 
vectors. Especially promising is the recent demon- 
stration of long-term myocardial transgene expres- 
sion induced by transcatheter intracoronary delivery 
of adeno-associated viral vectors. 42 The use Of this 
genome-integrating vector has been impeded until 
recently by the difficulty of obtaining high viral titers 
free of helper adenovirus contamination, but this 
may no longer be an obstacle. 43 If successful, al- 
iograft-targeted gene therapy alone or a combina- 
tion of gene transfer with time-limited pharmaco- 
logic interventions may prove to be an important 
alternative to conventional systemic immunosup- 
pression. 
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